Table 1.

Model assumptions

Non-persisters were assumed to either switch, undergo surgical operations or remain uncontrolled

Switchers and patients having surgical operations were assumed to have controlled symptoms

At treatment initiation (the start of the model), all patients were assumed to incur one visit to a GP and 1.5 visits to a specialist (urologist) [17]

Switchers were assumed to have one GP visit, 1.5 visits to a specialist (urologist) and one urodynamic test [17]

Patients who switched treatment were ascribed a drug acquisition cost, which was weighted by the market share of each treatment. The market share data were provided by Astellas [24]

One total probability of surgical operations was included and costs were applied [19], assuming that 50% of patients had onabotulinumtoxinA injection and 50% had SNS

Only non-persisters with uncontrolled symptoms were assumed to be at risk of co-morbidities (depression and UTI) [25]; the risk was applied in each cycle

Patients who were non-persistent and uncontrolled were assumed to have a 21.1% decrease in hours worked [25]

The persistence at 12 months was assumed to be the same for each treatment irrespective of the dose received [16]

The persistence at 12 months was assumed to be the same for trospium ER and IR formulations, and tolterodine ER and IR [16]

ER extended release, GP general practitioner, IR immediate release, SNS sacral nerve stimulation, UTI urinary tract infection